Tvardi Therapeutics Inc. (NASDAQ: TVRD) reported additional analysis from its Phase 2 REVERT IPF clinical trial showing patients treated with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE